GRI Bio (GRI) Stock Price, News & Analysis

Company Overview

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Key Stats

• Today's Range: $1.66 to $1.77
• 50-Day Range: $1.38 to $2.32
• 52-Week Range: $1.36 to $80.36
• Volume: 27,534 shs
• Average Volume: 400,238 shs
• Market Capitalization: $3.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.00
• Consensus Rating: Hold

GRI Bio Stock Analysis - MarketRank™

GRI Bio scored higher than 65% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

GRI Bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

GRI Bio has a consensus price target of $32.00, representing about 1,816.2% upside from its current price of $1.67.

Amount of Analyst Coverage

GRI Bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for GRI Bio are expected to grow in the coming year, from ($4.77) to ($2.54) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GRI Bio is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GRI Bio is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GRI Bio has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.81% of the float of GRI Bio has been sold short.

Short Interest Ratio / Days to Cover

GRI Bio has a short interest ratio ("days to cover") of 4.45.

Change versus previous month

Short interest in GRI Bio has recently decreased by 12.72%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GRI Bio does not currently pay a dividend.

Dividend Growth

GRI Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 3.00

News Sentiment

GRI Bio has a news sentiment score of 3.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for GRI Bio this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for GRI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GRI Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.73% of the stock of GRI Bio is held by insiders.

Percentage Held by Institutions

33.95% of the stock of GRI Bio is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 8/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:GRI
• Previous Symbol: NASDAQ:VLON
• CIK: 1824293
• Web: www.vallon-pharma.com
• Phone: 267-607-8255
• Fax: N/A
• Employees: 1
• Year Founded: 2009

Price Target and Rating

• Average Price Target for GRI Bio: $32.00
• High Price Target: $32.00
• Low Price Target: $32.00
• Potential Upside/Downside: +1,816.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($38.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.96 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -134.03%
• Return on Assets: -106.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.30
• Quick Ratio: 14.21

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.70 per share
• Price / Book: 0.36

Miscellaneous

• Outstanding Shares: 2,190,000
• Free Float: 1,995,000
• Market Cap: $3.66 million
• Optionable: Not Optionable
• Beta: -1.21